MedTrace Logo

Azacitidine in Treating Patients With Chronic Myelomonocytic Leukemia

NCT01235117 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2013-08-26

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy, such as azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.

PURPOSE: This phase II trial is studying the side effects of azacitidine and to see how well it works in treating patients with chronic myelomonocytic leukemia.

Conditions

Interventions

DRUG

azacitidine

OTHER

laboratory biomarker analysis

Sponsors & Collaborators

  • University of Leeds

    lead OTHER

Principal Investigators

  • David T. Bowen, MD · Leeds Cancer Centre at St. James's University Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2012-12-31
Completion
2013-05-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01235117 on ClinicalTrials.gov